AJ Collings, AJ Tebb, CM Elwood, G McLauchlan, IK Ramsey, JR Helm, LA Boden, ME Herrtage, PE Frowde, TD Parkin
To examine factors that might influence survival in the medical management of ADH, with particular emphasis on treatment selection.
Retrospective analysis of clinical records.
There was no statistically significant difference between the survival times of 13 dogs treated only with mitotane when compared with 22 dogs treated only with trilostane. The median survival time for animals treated with trilostane was 353 days (95% confidence interval [CI] 95-528 days), whereas it was 102 days (95% CI 43-277 days) for mitotane. Metastatic disease was detected in 8 of 37 dogs. There was a significantly lower probability of survival for dogs with metastatic disease when compared with those without metastatic disease (P < .001).